Company Filing History:
Years Active: 2025
Title: The Innovations of Matt Lundberg
Introduction
Matt Lundberg is an accomplished inventor based in San Mateo, California. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on innovative solutions for treating cancer and autoimmune diseases.
Latest Patents
Lundberg holds a patent for CD25 antibodies. This patent provides antibodies that specifically bind to CD25, along with methods for making and using these antibodies. The CD25 antibodies may be utilized therapeutically to treat various conditions, including cancer and autoimmune diseases. Notably, these antibodies can disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor. They bind to a different epitope than Daclizumab or Baciliximab and exhibit a higher affinity for CD25 at a pH lower than 7.4, particularly around a pH of 6.5.
Career Highlights
Lundberg is currently associated with Ibio Limited, where he continues to advance his research and development efforts. His innovative approach and dedication to improving therapeutic options have positioned him as a notable figure in his field.
Collaborations
Lundberg collaborates with talented individuals such as Phung Tu Gip and Bing Li. Their combined expertise enhances the potential for groundbreaking advancements in biotechnology.
Conclusion
Matt Lundberg's contributions to the field of biotechnology, particularly through his patent on CD25 antibodies, demonstrate his commitment to innovation and therapeutic development. His work has the potential to significantly impact the treatment of cancer and autoimmune diseases.